Treatment of connective tissue disease-associated interstitial lung disease

Clinical Pulmonary Medicine

Volumn 16, Issue 2, 2009, Pages 74-80

  Fischer, Aryeh ^a,b,c,d   Brown, Kevin K ^a,b,d   Frankel, Stephen K ^a,b,c,d  

^a Autoimmune Lung Disease Center   (United States)

^b Interstitial Lung Disease Program   (United States)

^c NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

Connective tissue disease; Interstitial lung disease; Treatment

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTIEMETIC AGENT; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ENDOTHELIN RECEPTOR ANTAGONIST; ETANERCEPT; INFLIXIMAB; INFLUENZA VACCINE; MESNA; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHOSPHODIESTERASE INHIBITOR; PLACEBO; PNEUMOCOCCUS VACCINE; PREDNISOLONE; PROSTANOID; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; STEROID; TACROLIMUS;

BLADDER DISEASE; BONE DENSITY; CLINICAL FEATURE; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; DIETARY INTAKE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERABILITY; DYSPNEA; ENTERITIS; GASTROESOPHAGEAL REFLUX; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INFLUENZA; INTERSTITIAL LUNG DISEASE; KINESIOTHERAPY; LOW DRUG DOSE; LUNG BIOPSY; LUNG DISEASE; LUNG FUNCTION TEST; LUNG LAVAGE; OXYGEN THERAPY; PNEUMONIA; PROGNOSIS; PSORIASIS; PULMONARY HYPERTENSION; PULMONARY REHABILITATION; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SMOKING CESSATION; UNSPECIFIED SIDE EFFECT;

EID: 67650403523     PISSN: 10680640     EISSN: None     Source Type: Journal    
DOI: 10.1097/CPM.0b013e31819b5400     Document Type: Review

References (82)

1. Lamblin C, Bergoin C, Saelens T, et al. Interstitial lung diseases in collagen vascular diseases. Eur Respir J Suppl. 2001;32:69s-80s.
2. Tzelepis GE, Toya SP, Moutsopoulos HM. Occult connective tissue diseases mimicking idiopathic interstitial pneumonias. Eur Respir J. 2008;31:11-20.
3. White B. Interstitial lung disease in scleroderma. Rheum Dis Clin North Am. 2003;29:371-390.
4. American Thoracic Society/European Respiratory Society International Mul-tidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002;165:277-304.
5. Park JH, Kim DS, Park IN, et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med. 2007;175:705-711.
6. Lee HK, Kim DS, Yoo B, et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest. 2005;127: 2019-2027.
7. Flaherty KR, Colby TV, Travis WD, et al. Fibroblastic foci in usual interstitial pneumonia: idiopathic versus collagen vascular disease. Am J Respir Crit Care Med. 2003;167:1410-1415.
8. Steen VD. Auto-antibodies in systemic sclerosis. Semin Arthritis Rheum. 2005;35:35-42.
9. Flaherty KR, Mumford JA, Murray S, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2003;168:543-548.
10. Collard HR, King TE Jr, Bartelson BB, et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2003;168:538-542.
11. Latsi PI, du Bois RM, Nicholson AG, et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med. 2003;168:531-537.
12. Bouros D, Wells AU, Nicholson AG, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med. 2002;165:1581-1586.
13. Hallstrand TS, Boitano LJ, Johnson WC, et al. The timed walk test as a measure of severity and survival in idiopathic pulmonary fibrosis. Eur Respir J. 2005;25:96-103.
14. Eaton T, Young P, Milne D, et al. Six-minute walk, maximal exercise tests: reproducibility in fibrotic interstitial pneumonia. Am J Respir Crit Care Med. 2005;171:1150-1157.
15. Buch MH, Denton CP, Furst DE, et al. Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test. Ann Rheum Dis. 2007;66:169 -173.
16. Lynch DA, Travis WD, Muller NL, et al. Idiopathic interstitial pneumonias: CT features. Radiology. 2005;236:10-21.
17. Kocheril SV, Appleton BE, Somers EC, et al. Comparison of disease progression and mortality of connective tissue disease-related interstitial lung disease and idiopathic interstitial pneumonia. Arthritis Rheum. 2005; 53:549-557.
18. Lynch DA. Quantitative CT of fibrotic interstitial lung disease. Chest. 2007;131:643-644.
19. Silver RM, Miller KS, Kinsella MB, et al. Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am J Med. 1990;88: 470-476.
20. Strange C, Bolster MB, Roth MD, et al. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Respir Crit Care Med. 2008;177:91-98.
21. Goh NS, Veeraraghavan S, Desai SR, et al. Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression. Arthritis Rheum. 2007;56:2005-2012.
22. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354:2655-2666.
23. Hoyles RK, Ellis RW, Wellsbury J, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 2006;54:3962-3970.
24. Walker WC, Wright V. Diffuse interstitial pulmonary fibrosis and rheumatoid arthritis. Ann Rheum Dis. 1969;28:252-259.
25. Holgate ST, Glass DN, Haslam P, et al. Respiratory involvement in systemic lupus erythematosus. A clinical and immunological study. Clin Exp Immunol. 1976;24:385-395.
26. Sullivan WD, Hurst DJ, Harmon CE, et al. A prospective evaluation emphasizing pulmonary involvement in patients with mixed connective tissue disease. Medicine (Baltimore). 1984;63:92-107.
27. Patterson CD, Harville WE, Pierce JA. Rheumatoid lung disease. Ann Intern Med. 1965;62:685-697.
28. Steen VD, Medsger TA Jr. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum. 1998;41:1613-1619.
29. Tsokos GC. Immunomodulatory treatment in patients with rheumatic diseases: mechanisms of action. Semin Arthritis Rheum. 1987;17:24-38.
30. Austin HA III, Klippel JH, Balow JE, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med. 1986;314: 614-619.
31. Reinhold-Keller E, Kekow J, Schnabel A, et al. Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis. Arthritis Rheum. 1994;37:919-924.
32. Silver RM, Warrick JH, Kinsella MB, et al. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol. 1993;20:838-844.
33. Akesson A, Scheja A, Lundin A, et al. Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum. 1994;37:729-735.
34. Schnabel A, Reuter M, Gross WL. Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases. Arthritis Rheum. 1998;41:1215-1220.
35. White B, Moore WC, Wigley FM, et al. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med. 2000;132:947-954.
36. Steen VD, Lanz JK Jr, Conte C, et al. Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study. Arthritis Rheum. 1994; 37:1290-1296.
37. Giacomelli R, Valentini G, Salsano F, et al. Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol. 2002;29: 731-736.
38. Pakas I, Ioannidis JP, Malagari K, et al. Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheumatol. 2002;29: 298-304.
39. Tashkin DP, Elashoff R, Clements PJ, et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med. 2007;176:1026-1034.
40. Furst DE, Clements PJ. Immunosuppressives. In: Hochberg MC, Silman AJ, Smolen JS, et al, eds. Rheumatology. 3rd ed. Spain: Mosby: 2003;439-448.
41. Willkens RF, Urowitz MB, Stablein DM, et al. Comparison of azathioprine, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum. 1992;35: 849-856.
42. Felson DT, Anderson J. Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis. Results of a pooled analysis. N Engl J Med. 1984;311:1528-1533.
43. Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behcet's syndrome. N Engl J Med. 1990;322:281-285.
44. Nicholls A, Snaith ML, Maini RN, et al. Proceedings: controlled trial of azathioprine in rheumatoid vasculitis. Ann Rheum Dis. 1973;32:589-591.
45. Nadashkevich O, Davis P, Fritzler M, et al. A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol. 2006;25:205-212.
46. Dheda K, Lalloo UG, Cassim B, et al. Experience with azathioprine in systemic sclerosis associated with interstitial lung disease. Clin Rheumatol. 2004;23:306-309.
47. Raghu G, Depaso WJ, Cain K, et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis. 1991;144: 291-296.
48. Cohen JM, Miller A, Spiera H. Interstitial pneumonitis complicating rheumatoid arthritis. Sustained remission with azathioprine therapy. Chest. 1977; 72:521-524.
49. Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2005;353:2229-2242.
50. Stolk JN, Boerbooms AM, de Abreu RA, et al. Reduced thiopurine methyl-transferase activity and development of side effects of azathioprine treatment in patients with rheumatoid arthritis. Arthritis Rheum. 1998;41:1858 -1866.
51. Furst DE. Leflunomide, mycophenolic acid and matrix metalloproteinase inhibitors. Rheumatology (Oxford). 1999;38(suppl 2):14 -18.
52. Chan TM, Li FK, Tang CS, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med. 2000;343:1156-1162.
53. Swigris JJ, Olson AL, Fischer A, et al. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest. 2006;130:30 -36.
54. Liossis SN, Bounas A, Andonopoulos AP. Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology (Oxford). 2006;45:1005-1008.
55. Zamora AC, Wolters PJ, Collard HR, et al. Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir Med. 2008;102: 150-155.
56. Gerbino AJ, Goss CH, Molitor JA. Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest. 2008;133:455-460.
57. Tugwell P, Pincus T, Yocum D, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. N Engl J Med. 1995;333:137-141.
58. Wells G, Tugwell P. Cyclosporin A in rheumatoid arthritis: overview of efficacy. Br J Rheumatol. 1993;32(suppl 1):51-56.
59. Clements PJ, Lachenbruch PA, Sterz M, et al. Cyclosporine in systemic sclerosis. Results of a forty-eight-week open safety study in ten patients. Arthritis Rheum. 1993;36:75-83.
60. BenEzra D, Cohen E, Chajek T, et al. Evaluation of conventional therapy versus cyclosporine A in Behcet's syndrome. Transplant Proc. 1988;20:136-143.
61. Oddis CV, Sciurba FC, Elmagd KA, et al. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet. 1999;353:1762-1763.
62. Wilkes MR, Sereika SM, Fertig N, et al. Treatment of antisynthetase- associated interstitial lung disease with tacrolimus. Arthritis Rheum. 2005; 52:2439-2446.
63. O'Dell JR. Methotrexate use in rheumatoid arthritis. Rheum Dis Clin North Am. 1997;23:779-796.
64. Constantin A, Loubet-Lescoulie P, Lambert N, et al. Anti-inflammatory and immunoregulatory action of methotrexate in the treatment of rheumatoid arthritis: evidence of increased interleukin-4 and interleukin-10 gene expression demonstrated in vitro by competitive reverse transcriptase-polymerase chain reaction. Arthritis Rheum. 1998;41:48-57.
65. Carson CW, Cannon GW, Egger MJ, et al. Pulmonary disease during the treatment of rheumatoid arthritis with low dose pulse methotrexate. Semin Arthritis Rheum. 1987;16:186-195.
66. Koopman WJ. Dawn of the era of biologics in the treatment of the rheumatic diseases. Arthritis Rheum. 2008;58:S75-S78.
67. Toussirot E, Wendling D. The use of TNF-alpha blocking agents in rheumatoid arthritis: an overview. Expert Opin Pharmacother. 2004;5:581-594.
68. Villeneuve E, St-Pierre A, Haraoui B. Interstitial pneumonitis associated with infliximab therapy. J Rheumatol. 2006;33:1189-1193.
69. Peno-Green L, Lluberas G, Kingsley T, et al. Lung injury linked to etanercept therapy. Chest. 2002;122:1858-1860.
70. Hagiwara K, Sato T, Takagi-Kobayashi S, et al. Acute exacerbation of preexisting interstitial lung disease after administration of etanercept for rheumatoid arthritis. J Rheumatol. 2007;34:1151-1154.
71. Huggett MT, Armstrong R. Adalimumab-associated pulmonary fibrosis. Rheumatology (Oxford). 2006;45:1312-1313.
72. Vassallo R, Matteson E, Thomas CF Jr. Clinical response of rheumatoid arthritis-associated pulmonary fibrosis to tumor necrosis factor-alpha inhibition. Chest. 2002;122:1093-1096.
73. Ochmann U, Nowak D. [Long term effects of pulmonary rehabilitation in COPD and interstitial lung disease-synopsis of databases since 1990]. Dtsch Med Wochenschr. 2007;132:627-632.
74. Singer NG, McCune WJ. Prevention of infectious complications in rheumatic disease patients: immunization, Pneumocystis carinii prophylaxis, and screening for latent infections. Curr Opin Rheumatol. 1999;11:173-178.
75. Harris-Eze AO, Sridhar G, Clemens RE, et al. Oxygen improves maximal exercise performance in interstitial lung disease. Am JRespir Crit Care Med. 1994;150:1616-1622.
76. Ryu JH, Krowka MJ, Pellikka PA, et al. Pulmonary hypertension in patients with interstitial lung diseases. Mayo Clin Proc. 2007;82:342-350.
77. Arcasoy SM, Christie JD, Ferrari VA, et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med. 2003;167:735-740.
78. Shapiro S. Management of pulmonary hypertension resulting from interstitial lung disease. Curr Opin Pulm Med. 2003;9:426-430.
79. Cohen S. The gastrointestinal manifestations of scleroderma: pathogenesis and management. Gastroenterology. 1980;79:155-166.
80. Marie I, Dominique S, Levesque H, et al. Esophageal involvement and pulmonary manifestations in systemic sclerosis. Arthritis Rheum. 2001;45: 346-354.
81. Curtiss PH Jr, Clark WS, Herndon CH. Vertebral fractures resulting from prolonged cortisone and corticotropin therapy. J Am Med Assoc. 1954;156: 467-469.
82. Recommendations for the prevention and treatment of glucocorticoid- induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum. 2001; 44:1496-1503.